ORIGIN STUDY (OUTCOME REDUCTION WITH INITIAL GLARGINE INTERVENTION) 2 YEARS LATER: WHAT’S NEW?


I.V. Glinkina

SBEI HPE «First MSMU n.a. I.M. Sechenov" of RMPH, Moscow
The article considers the main outcomes of the ORIGIN study, the main results of which were first presented in 2012. The main purpose of this study was to evaluate the effects of therapy with insulin glargine (IG) compared with standard glucose-lowering therapy (in combination with ω-3 polyunsaturated fatty acids or placebo) in relation to the reducing the risk of cardiovascular diseases (CVD) and / or mortality in patients with prediabetes or "early" type 2 diabetes mellitus (DM) and high cardiovascular risk. Subsequently, ORIGIN study was expanded through several additional studies and a subanalyses, the results of which are discussed in this review. It has been shown that treatment with IG provides a stable, long-term glycemic control, with neutral impact on the cardiovascular outcomes, relatively low risk of hypoglycemia and small weight gain. Achievement of the fasting normoglycemia as a result of therapy with IG allows to reduce the risk of microvascular complications. Compared with standard therapy, severe hypoglycemia during therapy with the IG is less associated with the cardiovascular outcomes. Therapy with IG slows the progression of atherosclerosis, but has no effect on the progression of cognitive dysfunction. The presence of long-term effects of the therapy applied in the ORIGIN study will be known after the analysis of the results of ORIGINALE study (follow-up over participants of the ORIGIN study).

About the Autors


I.V. Glinkina – PhD in Medical Sciences, Assistant Professor at the Department of Endocrinology of the Medical Faculty SBEI HPE First MSMU n.a. I.M. Sechenov of RMPH


Similar Articles


Бионика Медиа